Post-Transplant Cyclophosphamide (PTCY) Results in Remarkably Low Incidence of Chronic Graft-Versus-Host Disease in Unrelated or Matched Sibling Donor Stem Cell Transplantation without Compromising Immune Reconstitution and Graft-Versus-Leukemia Effect

PTCY was first applied in the haploidentical stem cell transplantation (SCT) setting and is gradually being used in mismatched unrelated or fully matched donor transplants. We prospectively tested this approach in SCT from matched or mismatched unrelated (MUD/MMUD) and matched sibling donors (MSD) to reduce the incidence of acute and especially chronic graft-vs-host disease (GVHD).From 01/2021 to 05/2023, 51 consecutive patients, aged 18-69 (median 52) years, received allogeneic SCT with PTCY for AML/MDS (n=36), NHL/CLL (n=2), primary myelofibrosis (n=2), CML (n=2), or ALL (n=9).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ifigeneia Tzannou, Ioannis Tsonis, Tatiana Tzenou, Aikaterini Souravla, Maria Katsareli, Natali El Gotmi, Ismini Darmani, Evridiki Theodorou, Maria-Eleni Karatza, Maria Garofalaki, Zoi Poulopoulou, Marina Papageorgiou, Soultana Tryfonidou, Panagiotis Siam Tags: 212 Source Type: research